Recon: Pazdur reportedly intervened in Replimune decision; Eli Lilly to sell New Jersey facility

• The murkiness of drug companies’ price transparency reports (STAT)
• FDA’s top cancer drug regulator played key role in rejection of Replimune therapy, officials say (STAT)
• After surprise CRL, Replimune says it's waiting for FDA on a path forward for cancer treatment (Endpoints)
• FDA to stress opioids’ risk of overdose, death in new medication safety labels (STAT)
• The FDA’s plan on fluoride supplements is bad science (STAT)
• Trump Administration Blocks Funding for CDC Health Programs (The Wall Street Journal)
• Wegovy maker Novo hit with investor class action over revenue forecast cut (Reuters)

• Gates Foundation pledges $2.5 billion to women’s health initiatives (STAT)
• Swiss Stocks Decline on US Tariffs, Push for Lower Drug Prices (Bloomberg)
• Denmark’s Economy Runs on Novo. Will the Drugmaker’s Troubles Slim It Down? (Bloomberg)
• UK MHRA Takes Stock, Seeks CMSO And Reveals Device Innovation Early Access Thinking (MedTech Insight)
• India's Aurobindo Pharma reports profit fall as cost rise outweighs sales growth (Reuters)

• Eli Lilly confirms plan to sell NJ plant (Fierce Pharma)
• Uncertainty clouds the San Diego biotech hub, with jobs and capital scarce (STAT)
• The U.S. needs a revolution to harness the potential of GLP-1s for weight loss (STAT)
• Hims and Hers beats quarterly profit on steady subscription growth (Reuters)
• Biogen is building a 'ventures' team to 'keep early portfolio externalized' (Endpoints)
• Hansa says small trial shows its investigational drug could expand use of Sarepta’s Elevidys (Endpoints)
• BioNTech sales grow, braces for FDA decision on updated Covid vaccine (Endpoints)
• Lilly’s Push to $1 Trillion Derailed by Trade Risks and Obesity Drug Speedbumps (Bloomberg)
• Noom launches low dose of compounded weight-loss drug for $119 (Reuters)
• Lenz's Vizz wins FDA approval to crack 'large, untapped' market for presbyopia (Fierce Pharma)

• Eating disorder telehealth startup Equip raises $47M (Endpoints)
• Heartflow prices IPO, aiming to net about $180M (MedTech Dive)
• Dexcom Builds Momentum Ahead of 15-Day G7 Launch, Eyes AI and G8 for Growth (MedTech Insight)
• J&J MedTech’s Digital Head Pushes for Smarter, Standardized ORs With AI and Open Tech (MedTech Insight)

• Beverages become essential to consumer wellness routines: report (Food Dive)
• Utz Brands to close facility as part of supply chain transformation (Food Business News)

• State AGs sue Trump, HHS over gender-affirming care restrictions (STAT)
• AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills (STAT)
• Representatives of expert groups to be barred from work supporting CDC’s vaccine advisers (STAT)
• MAGA influencers take a sudden interest in Medicare Advantage reforms, echoing a dark money group (STAT)
• White House has no plan to mandate IVF care, despite campaign pledge (The Washington Post)